Paul Nager, DO
Cardiovascular Disease · Overland Park, KSNPI 1821047440
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,270 of the $10,004 with a category attached, or 82.7%. It is spread thinly across 40 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,358 and has fallen 70.0% since, to $1,009 in 2025.
Across 392 payments — averaging $25.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$2K
- Amgen$1K
- Boston Scientific$1K
- E.r. Squibb & Sons, L.L.C.$501
- Novartis$500
- Astellas Pharma US Inc$440
- plus $4K from 34 others
What the payments were for
- Consulting fees$400%
- Travel & lodging$1,22612%
- Food & beverage$8,27083%
- Education$4675%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,004 in reported general payments places this provider in the 85th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 222 | $225,172 |
| Repatha SureclickEvolocumab | 153 | $193,480 |
| JardianceEmpagliflozin | 89 | $94,535 |
| CamzyosMavacamten | 11 | $90,317 |
| XareltoRivaroxaban | 58 | $75,516 |
| EntrestoSacubitril/Valsartan | 47 | $44,182 |
| Praluent PenAlirocumab | 22 | $31,873 |
| VascepaIcosapent Ethyl | 34 | $16,754 |
| BrilintaTicagrelor | 24 | $13,106 |
| Ezetimibe | 378 | $6,932 |
| Atorvastatin Calcium | 420 | $3,727 |
| Metoprolol Succinate | 307 | $3,271 |
| Carvedilol | 344 | $2,793 |
| Losartan Potassium | 241 | $1,994 |
| Rosuvastatin Calcium | 248 | $1,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $232 | $225,172222 claims |
| Boehringer IngelheimJardiance | $112 | $94,53589 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $501 | $90,31711 claims |
| Johnson & JohnsonXarelto | $437 | $75,51658 claims |
| NovartisEntresto | $500 | $44,18247 claims |
| AstraZenecaBrilinta | $133 | $13,10624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Overland Park
- Vasvi SinghOverland Park$405K
- Rachel SoslandOverland Park$33K
- Ahmed ElballatOverland Park$22K
- Ronnie SmallingOverland Park$9K
- van JonesOverland Park$7K
- Alan SchneiderOverland Park$6K
- Theodore PopeOverland Park$5K
- Stephen BloomOverland Park$5K
- James MarcumOverland Park$4K
- Bassem ChehabWichita$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.